INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors

Business Wire 12-Dec-2024 3:00 PM

Law Offices of Howard G. Smith announces an investigation on behalf of Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX) investors concerning the Company's possible violations of federal securities laws.

On or about February 8, 2024, Kyverna conducted its initial public offering ("IPO"), selling 14.5 million shares of common stock for $22.00 per share.

On June 14, 2024, Kyverna provided an update on its lupus nephritis drug, KYV-101, and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite having previously touted patient improvement.

Investors have suffered significant losses since the IPO.

If you purchased Kyverna securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212050459/en/